Data on patients with inflammatory bowel disease (IBD) and depression and their unaffected siblings could shed light on the gut-brain axis influence on the pathophysiology of IBD. A team, led by Bing Zhang, MD, Department of Medicine, Division of Gastrointestinal and Liver Disease, Keck School of Medicine, University of Southern California, identified the risk of depression among patients with IBD and their unaffected siblings, as well as the risk of IBD among patients with depression and their unaffected siblings.
Author: Praveen Suthrum
Virtual Incision Corp. announced FDA approval of an Investigational Device Exemption supplement for its final stage clinical study of the MIRA Platform for bowel resection procedures. According to a company press release, MIRA is the first-of-its-kind, miniaturized robotic-assisted surgery (RAS) platform, which offers the benefits of RAS without the inefficiencies of traditional robotics. The platform received favorable interim trial safety profile reports.
The FDA granted a 510(k) clearance to the SMART Medical Systems G-EYE Colonoscope for use in the U.S. market, based on the FDA-cleared PCF Colonoscope Series (Olympus), according to a press release. The G-EYE Colonoscope can now be used in conjunction with the most commonly used colonoscope models from brands such as Fujifilm, Olympus and Pentax Medical.
The US Food and Drug Administration (FDA) on Friday issued a draft guidance to industry on developing drugs or biologics to treat celiac disease (CeD) as a complement to a gluten-free diet.The guidance was developed by FDA’s Division of Gastroenterology in the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). The document includes details on eligibility criteria, trial design, considerations for efficacy and safety, and clinical outcome assessments. It does not address the development of drugs intended to replace a gluten-free diet or for treating asymptomatic patients with minimal histologic inflammation.
Experiments have shown that sleep position influences the occurence of nocturnal gastric reflux, with the left lateral decubitus position being the most beneficial.
Three gastroenterologists joined Becker’s to discuss what’s drawing gastroenterologists to private practice. Editor’s note: These responses were edited lightly for brevity and clarity. Pankaj Vashi, MD. Chief of gastroenterology/nutrition department and vice chief of staff at CTCA Chicago: Gastroenterologist compensation impacts recruitment. Due to the significant shortage of well-trained gastroenterologists, the private practice groups are willing to pay much more than the academic or institutional hospital systems. New graduates are getting not only well compensated, but also offered a great work-life balance in private practice. That is why more gastroenterologists are driven to private practices.
As clinicians, providing the best quality of care is paramount. But when it comes to procedure-intensive specialties, medical malpractice is a notable concern. So what do we need to know about the common malpractice claims in the GI field, and how can we mitigate the risk of those claims? To find out, Dr. Peter Buch is joined by Dr. Michael Weinstein, President and CEO of Capital Digestive Care.
My perspective on gastroenterology is broad and deep – and not just because I once removed $420 from a patient’s stomach! As a practicing gastroenterologist, I specialize in irritable bowel syndrome (IBS) and related difficult-to-manage conditions. For a decade, I ran operations for a large gastroenterology practice. Academically, I focus on the broad forces shaping gastrointestinal (GI) care.
In this video, Gary W. Herschman, JD, discusses the increase in physician transactions with private equity firms and four major reasons for this trend. “The first driver of this is the ability to monetize the true value of a physician practice,” Herschman, an attorney in the health care and life sciences practice of Epstein Becker Green, told Healio.
AGA has released a new special issue of Gastroenterology, Entering the Era of Disease Modification in Inflammatory Bowel Disease (IBD). Edited by Drs. Alisa L. Hart and David T. Rubin, the issue includes selected articles on disease characterization, evolving treatment goals, disease assessment, monitoring and treatment.